Skip to main content
Year archive

NEUREN PHARMACEUTICALS LIMITED — 2020 filings

All 56 regulatory filings released by NEUREN PHARMACEUTICALS LIMITED (NEU) in 2020, sourced directly from the official regulator.

56 Filings
2020 Period
2020 filings (56)
Filing Released Lang
Positive opinion for all 3 Orphan applications in Europe 2 pages 150.5KB
Regulatory Filings
2020-12-06 English
Notification of investor briefing webinar 1 page 95
Regulatory Filings
2020-12-06 English
Approval received for final stage of NNZ-2591 clinical trial 2 pages 134.8KB
Regulatory Filings
2020-11-18 English
Quarterly report and cash flow statement for Q3 2020 9 pages 223.9KB
Interim / Quarterly Report
2020-10-28 English
Neuren requests Orphan designations for NNZ-2591 in Europe 2 pages 148.7KB
Regulatory Filings
2020-09-28 English
Neuren initiates manufacture of NNZ-2591 for Phase 2 trials 2 pages 148.1KB
Capital/Financing Update
2020-09-21 English
Half Yearly Report and Accounts 14 pages 283.8KB
Interim / Quarterly Report
2020-08-25 English
Half-year Shareholder Update 3 pages 239.2KB
Interim / Quarterly Report
2020-08-25 English
Corporate presentation, 18 August 2020 32 pages 860.2KB
Investor Presentation
2020-08-17 English
Change of Director's Interest Notice 2 pages 36.6KB
Director's Dealing
2020-08-10 English
Change of Director's Interest Notice 2 pages 36.8KB
Director's Dealing
2020-08-06 English
Appendix 2A 15 pages 164.1KB
Regulatory Filings
2020-08-06 English
Completion of Share Purchase Plan 1 page 122.9KB
Capital/Financing Update
2020-08-04 English
Appointment of CFO & Company Secretary 1 page 121.4
Board/Management Information
2020-07-29 English
Q2 2020 Activity Report and Cash Flow Report 8 pages 199.6KB
Interim / Quarterly Report
2020-07-26 English
Publications and presentations for trofinetide and NNZ-2591 2 pages 129.3KB
Regulatory Filings
2020-07-13 English
Announcement of buy-back - Appendix 3C 4 pages 78.4KB
Transaction in Own Shares
2020-07-13 English
Final share buy-back notice - Appendix 3F 2 pages 70.4KB
Transaction in Own Shares
2020-07-13 English
Appendix 3G 12 pages 134.3KB
Share Issue/Capital Change
2020-07-12 English
Share Purchase Plan Offer Booklet 10 pages 209.0KB
Capital/Financing Update
2020-07-08 English
Appendix 2A 15 pages 169.8KB
Regulatory Filings
2020-07-05 English
Section 708A notice 1 page 168.3KB
Capital/Financing Update
2020-07-05 English
Electing to receive SPP documents by e-mail 2 pages 130.0KB
Regulatory Filings
2020-06-30 English
Neuren successfully completes $20m capital raising 2 pages 137.2KB
Capital/Financing Update
2020-06-28 English
Proposed issue of Securities - NEU 9 pages 36.5KB
Capital/Financing Update
2020-06-28 English
AGM Chairman's Address and CEO Presentation 22 pages 567.2KB
AGM Information
2020-06-28 English
Results of Meeting 1 page 64.1KB
Declaration of Voting Results & Voting Rights Announcements
2020-06-28 English
Trading Halt 2 pages 164.8KB
Capital/Financing Update
2020-06-24 English
Temporary enrolment pause ended in Phase 3 trial in the US 2 pages 235.5KB
Regulatory Filings
2020-06-15 English
Change of Director's Interest Notice 2 pages 36.4KB
Director's Dealing
2020-06-01 English
Change of Director's Interest Notice 2 pages 35.2KB
Director's Dealing
2020-05-31 English
Final Director's Interest Notice 2 pages 27.0KB
Director's Dealing
2020-05-28 English
Notice of Annual General Meeting/Proxy Form 15 pages 253.3KB
AGM Information
2020-05-27 English
Virtual AGM online guide 6 pages 1.2MB
AGM Information
2020-05-27 English
Neuren announces changes to leadership team 2 pages 135.6KB
Board/Management Information
2020-05-26 English
Neuren commences first clinical trial for NNZ-2591 2 pages 126.3KB
Regulatory Filings
2020-05-06 English
Annual Report 2019 56 pages 1.7MB
Annual Report
2020-04-28 English
Appendix 4G 11 pages 115.0KB
Governance Information
2020-04-28 English
Q1 2020 Activity Report 2 pages 137.5KB
Interim / Quarterly Report
2020-04-16 English
Appendix 4C - quarterly 5 pages 58.9KB
Interim / Quarterly Report
2020-04-16 English
Corporate presentation, 6 April 2020 38 pages 1.2MB
Investor Presentation
2020-04-05 English
First patent in Israel granted for trofinetide 1 pa
Regulatory Filings
2020-04-01 English
International institution acquires 14% of Neuren 1
Major Shareholding Notification
2020-03-25 English
Change of Director's Interest Notice 2 pages 36.5KB
Director's Dealing
2020-03-25 English
Temporary pause in new enrolments for LAVENDER trial in US 2 pages 203.5KB
Regulatory Filings
2020-03-23 English
Change of Director's Interest Notice 2 pages 36.5KB
Director's Dealing
2020-03-23 English
Trading Halt 2 pages 149.9KB
Regulatory Filings
2020-03-19 English
Neuren to capture substantially greater value after Phase 3 3 pages 145.4KB
Capital/Financing Update
2020-03-16 English
Additional information 1 page 100.8KB
Regulatory Filings
2020-03-09 English
Compelling results for 2591 dose ranging study in PMS model 4 pages 193.8KB
Capital/Financing Update
2020-03-05 English
Rare Pediatric Disease designation received from FDA 3 pages 182.5KB
Capital/Financing Update
2020-03-03 English
Commentary on potential benefit to Neuren of RPD designation 2 pages 159.8KB
Capital/Financing Update
2020-03-03 English
Appendix 4E and 2019 full year accounts 31 pages 1.2MB
Annual Report
2020-02-25 English
5 Orphan Drug programs and Rett in Phase 3 funded by partner 4 pages 831.3KB
Annual Report
2020-02-25 English
Update on trofinetide Phase 3 trial in Rett syndrome 2 pages 104.3KB
Regulatory Filings
2020-02-18 English
Appendix 4C - quarterly 5 pages 59.4KB
Interim / Quarterly Report
2020-01-27 English